Home > Newsletters > Drug Industry Daily > J&J’s Canagliflozin May Be More Effective Than AZ, BMS’ Dapagliflozin: Analyst
Drug Industry Daily
June 12, 2012 | Vol. 11 No. 115
J&J’s Canagliflozin May Be More Effective Than AZ, BMS’ Dapagliflozin: Analyst
Johnson & Johnson’s (J&J) Type 2 diabetes treatment canagliflozin appears to have a “modestly better” efficacy profile compared with its competitor, AstraZeneca and Bristol Myers Squibb’s (BMS) Forxiga, as the companies race to bring the first selective sodium glucose co-transport 2 (SGLT-2) inhibitor to market, an analyst says.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.